The mechanism of action of methylprednisolone in the treatment of multiple sclerosis
| Autor: | M. Stefanelli, J S Sloka |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Multiple Sclerosis
Transcription Genetic T-Lymphocytes medicine.medical_treatment Methylprednisolone Nitric oxide 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Immune system medicine Humans Cytotoxic T cell business.industry Multiple sclerosis Models Immunological medicine.disease Extravasation Neuroprotective Agents Cytokine Neurology chemistry 030220 oncology & carcinogenesis Immunology Tumor necrosis factor alpha Neurology (clinical) business Cell Adhesion Molecules 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Multiple Sclerosis Journal. 11:425-432 |
| ISSN: | 1477-0970 1352-4585 |
| DOI: | 10.1191/1352458505ms1190oa |
| Popis: | Methylprednisolone plays an important role in the current treatment of multiple sclerosis (MS), particularly in the acute phase of relapse. It acts in various ways to decrease the inflammatory cycle including: dampening the inflammatory cytokine cascade, inhibiting the activation of T cells, decreasing the extravasation of immune cells into the central nervous system, facilitating the apoptosis of activated immune cells, and indirectly decreasing the cytotoxic effects of nitric oxide and tumor necrosis factor alpha. This paper reviews the most recent observations on these mechanisms both to understand the disease mechanism and its treatment. As more becomes known about these mechanisms, it may become possible to design treatment regimes that are more specific towards both the individual and the disease state. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|